Dr. Barbara Jonischkeit and Dr. Claudia Luther take over the management of the state agency - 17/12/2024

Change at the top of BIOPRO Baden-Württemberg

For 22 years, Prof. Dr. Ralf Kindervater has been the Managing Director of BIOPRO Baden-Württemberg, the state agency that provides expertise to politics and state institutions in the fields of the healthcare industry, biotechnology, medical technology and the pharmaceutical industry. On January 1, 2025, he will hand over the reins to Dr. Barbara Jonischkeit and Dr. Claudia Luther.

Die BIOPRO Baden-Württemberg begleitet in den Jahren 2021 und 2022 die Gründung des "Baden-Württemberg-Center for Academic Drug Discovery" (BWCAD2).

Photon-counting technology - 01/02/2023

PC3 consortium: innovative computed tomography for Baden-Württemberg

The University Hospitals of Freiburg, Tübingen and Mannheim have been cooperating with each other since 2021 to test new types of computed tomography devices. With the help of photon-counting technology, the aim is not only to improve patient care, but also to encourage local companies to develop downstream data processing technologies.

Article - 15/10/2019

docdirekt – a smart way to contact a doctor in Baden-Württemberg

You feel unwell, but the family doctor’s practice is closed or it’s impossible to get an appointment at short notice. As part of their docdirekt project, the Baden-Württemberg Association of Statutory Health Insurance Physicians (in German: "Kassenärztliche Bundesvereinigung Baden-Württemberg (KVBW)) is now offering help for such cases. Everyone signed up to the statutory health insurance scheme will now be able to ring, contact via apps or…

Expert interview - 03/03/2021

Healthcare movers – the future of Baden-Württemberg's healthcare industry

The 'Healthcare Movers 2020 - Baden-Württemberg Report' reveals the potentials and challenges Baden-Württemberg healthcare companies encounter as the digital transformation of the healthcare market progresses. In an interview with Dr. Ariane Pott from BIOPRO, the authors of the report, Beatus Hofrichter and Dr. Ursula Kramer, explain what is required to take the major step towards becoming a digital avant-garde company.

A new network has been set up in Baden-Württemberg aimed at reducing animal experiments as well as further improving animal welfare. It combines new approaches and measures at the state’s biomedical research locations, which are expected to limit stress in laboratory animals and steadily reduce the number of animals used in research in line with the 3R principles of Replacement, Reduction, and Refinement.

The demand for skilled workers in Germany is high - especially in the healthcare sector. But the procedure for hiring and recognising qualifications is complex. In Baden-Württemberg, the Welcome Center Sozialwirtschaft Baden-Württemberg is one of the contact points for companies and professionals seeking advice on the process.

Gründung, Gründungsberatung, Gründungsunterstützung, Start-ups, Baden-Württemberg, Anlaufstellen,

Expert interview on NTDs – part 1 - 11/04/2019

Neglected tropical diseases – Carsten Köhler: impulses from Baden-Württemberg

More than one billion people worldwide suffer from neglected tropical diseases (NTDs). NTDs are mostly poverty-related infectious diseases that prevail in tropical countries due to lack of research and measures to detect, prevent and control them. Dr. Dr. Carsten Köhler reports on the political, economic and scientific contributions Germany and Baden-Württemberg can make to successfully change this situation.

Press release - 23/09/2022

Phytopharmaceuticals and valuable plant ingredients - opportunities for industry and agriculture in Baden-Württemberg

The "Phytopharmaceuticals and Valuable Plant Ingredients" initiative aims to make the key economic issue of phytopharmaceuticals more visible in Baden-Württemberg in order to gain a better understanding of the challenges and needs of the state’s pharmaceutical industry. The overall goal is to strengthen the use of secondary plant ingredients in valuable products and build on this to develop opportunities for Baden-Württemberg…

Kooperationsanbahnung ist eine Dienstleistung der BIOPRO Baden-Württemberg für Unternehmen und Forschungseinrichtungen

Installing the next digital generation of computed tomography at various Baden-Württemberg medical centres (PC3)

The ‘Photon-Counting’ (PC)-CT consortium received funding in the next round of funding from the Forum Health Region Baden-Württemberg. The aim of the new consortium was to install the image data infrastructure ‘teamplay digital health platform connect’ (tdhp) at four clinical sites for digital exchange in the follow-up project PC3-AIDA.

The Phytopharmaceuticals and Valuable Plant Ingredients initiative aims to further develop phytopharmaceuticals and valuable plant ingredients in Baden-Württemberg.

Press release - 24/04/2024

Strengthening the healthcare sector in the state: BIOPRO Baden-Württemberg networks itself strategically at a European level

BIOPRO has been supporting Baden-Württemberg as a healthcare location for many years and provides important incentives for its further development.  The state company has been a member of the Council of European Bioregions (CEBR) network since April 2024. Within the CEBR, BIOPRO aims to network with European cooperation partners in order to provide even better support for the innovative capacity of the healthcare industry in Baden-Württemberg.

Dr. Nicole Hoffmeister-Kraut, Minister of Economic Affairs, Labour and Tourism of Baden-Württemberg, together with Freiburg’s Mayor Martin Horn, gives the go-ahead for the construction project on the Georges-Köhler-Allee.

Sixteen leading life science and IT companies, all-new livestreamed presentations, and an informative career panel made for a successful EMBL Industry Day in its second year

Press release - 29/11/2022

Five European pilot regions are joining forces for the bioeconomy

BIOPRO Baden-Württemberg participates in the Horizon Europe ROBIN project to improve the participation of regional bioeconomy strategies and related policies across Europe.

Non-profit limited liability company creates institutional framework for interdisciplinary research collaboration, innovative technology development and outstanding healthcare in the Rhine-Neckar region.

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the pricing of an underwritten public offering of 15,925,000 ordinary shares at a public offering price of $11.00 per share.

he Robert Bosch Stiftung is celebrating its 60th anniversary in 2024. To commemorate this, the Foundation is holding an anniversary celebration today at its headquarters in Stuttgart. Among the guests are partners from the Foundation's charitable work as well as representatives from politics, business, and society, including members of the Bosch family and company.

Baden-Württemberg is currently home to 193 biotechnology companies, most of which specialise in so-called ‘red biotechnology’ - i.e. applications in the medical and pharmaceutical sectors. The biotech sector includes not only traditional biotechnology companies, but also companies from the fields of bioinformatics, diagnostics, analytics and biotechnological production.

Medical technology plays a key role in health and makes a contribution to improving quality of life. The spectrum of medical technology ranges from disposable products, IT-based applications to innovative technologies. In Baden-Württemberg, 836 companies are active in research, development and/or production in this field, making medical technology one of the most important economic sectors in the state.

Data generated by the healthcare system has enormous potential for improving the quality of patient-centered care. As part of the Health Data Scenarios project, Basel Area Business & Innovation worked with numerous experts from industry and academia in 2020 to develop ten scenarios of what future health data ecosystems could look like. These scenarios are now being discussed and validated together with experts and opinion leaders from…

Dossier - 26/03/2012

Nanobiotechnology

What is nanobiotechnology what is the difference between nanotechnology and nanobiotechnology and where and what nanobiotechnological research is being carried out in Germany and more particularly in Baden-Württemberg and which applications is it aimed at?

Dossier - 04/11/2013

Biotechnology driver of innovation in the pharmaceutical industry

The biotech industry is the innovative driver for a pharmaceutical industry that, due to the shift from blockbluster products to personalised medicine, now depends on new concepts. The production of new drugs using genetic engineering relies on knowledge gained from genomics, proteomics and systems biology and creates new treatment strategies that combine therapy and diagnostics (i.e. companion diagnostics) to provide a specific individualised…